Correlation Between SAB Biotherapeutics and Qualigen Therapeutics

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Qualigen Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Qualigen Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and Qualigen Therapeutics, you can compare the effects of market volatilities on SAB Biotherapeutics and Qualigen Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Qualigen Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Qualigen Therapeutics.

Diversification Opportunities for SAB Biotherapeutics and Qualigen Therapeutics

0.44

Correlation Coefficient

SAB Biotherapeutics  Qualigen Therapeutics

Very weak diversification

The 3 months correlation between SAB and Qualigen is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Qualigen Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Qualigen Therapeutics and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Qualigen Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Qualigen Therapeutics has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Qualigen Therapeutics go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Qualigen Therapeutics

Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 5.07 times more return on investment than Qualigen Therapeutics. However, SAB Biotherapeutics is 5.07 times more volatile than Qualigen Therapeutics. It trades about 0.02 of its potential returns per unit of risk. Qualigen Therapeutics is currently generating about -0.07 per unit of risk. If you would invest  9.00  in SAB Biotherapeutics on December 26, 2024 and sell it today you would lose (6.01) from holding SAB Biotherapeutics or give up 66.78% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	91.67%
Values	Daily Returns

SAB Biotherapeutics  vs.  Qualigen Therapeutics

SAB Biotherapeutics

Risk-Adjusted Performance

Very Weak

Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Qualigen Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Qualigen Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with SAB Biotherapeutics and Qualigen Therapeutics

The main advantage of trading using opposite SAB Biotherapeutics and Qualigen Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Qualigen Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qualigen Therapeutics will offset losses from the drop in Qualigen Therapeutics' long position.

The idea behind SAB Biotherapeutics and Qualigen Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.